# Debate prop_0624__gpt-5.6-high__mimo-v2.5-pro__s0__tpl_placement_active_20260320f

- topic_id: prop_0624
- proposition: Health systems should permit and reimburse AI-assisted clinical documentation and triage only if models meet publicly reported accuracy and bias benchmarks.
- model_pro: gpt-5.6-high
- model_con: mimo-v2.5-pro
- side_swap: False

## Turn 1: PRO Opening

- model: gpt-5.6-high
- raw_words: 329
- clipped_words: 329
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] A clinical AI can turn one silent error into a repeatable system failure. If a documentation assistant invents a medication or omits a warning, that mistake can propagate through the record. If a triage model systematically underrates pain or atypical symptoms in a subgroup, patients can wait precisely because the software appears objective. These are not ordinary spelling tools; they influence care.
[P1.2] Requiring demonstrated performance before permission and payment is therefore a basic safety floor, not hostility to innovation.
[P1.3] The benchmark should be fit for purpose: accuracy on the task the model is actually authorized to perform, and bias testing across clinically relevant patient groups. For documentation, that can include unsupported statements, important omissions, and correct capture of diagnoses or medications. For triage, it can include missed urgent cases and subgroup differences in false reassurance. The proposition does not demand perfection or one universal threshold.
[P1.4] It demands that health systems define acceptable standards and verify that a model clears them.
[P1.5] Public reporting is essential. Private assurances leave patients, clinicians, purchasers, and competing developers unable to distinguish reliable systems from polished demonstrations. Transparency reveals whether headline performance conceals failure among older patients, speakers of less common languages, or people with disabilities. It also permits independent scrutiny when models or clinical populations change.
[P1.6] Without public results, “trust us” becomes the business model.
[P1.7] Reimbursement makes this obligation stronger. Public and pooled health funds should not subsidize opaque products first and discover their weaknesses after widespread deployment. Payment also accelerates adoption, creates vendor lock-in, and places institutional pressure on clinicians to use what has been purchased. The evidentiary gate must come before that scale.
[P1.8] Benchmarks can be updated, tailored to risk, and measured on the full human-AI workflow. Promising tools may still be tested in controlled evaluations before routine permission and reimbursement. That preserves innovation while placing the burden where it belongs: on vendors and health systems seeking authority and public money, not on patients unknowingly asked to serve as the test set.

## Turn 2: CON Opening

- model: mimo-v2.5-pro
- raw_words: 336
- clipped_words: 336
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8], [C1.9]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] The proposition sounds prudent until you consider what it actually does: it creates a static checkpoint that will slow deployment of beneficial tools, generate false confidence in systems that pass, and crowd out the continuous monitoring that actually protects patients.
[C1.2] Start with the validation paradox. You cannot build reliable benchmarks for clinical AI without deploying these tools in real clinical contexts—capturing the actual distribution of patients, documentation styles, and clinical complexity that lab settings miss. PRO says models must clear benchmarks before routine permission and reimbursement.
[C1.3] But rigorous benchmarks require the very deployment data that PRO's gate blocks. The result is a regulatory freeze favoring whoever had the resources to test in controlled environments, not whoever built the most clinically useful tool.
[C1.4] Second, benchmarks game themselves. When a single published number determines market access, vendors optimize for that number. This is not speculation—it is Goodhart's Law applied to medicine. A triage model can be tuned to minimize false negatives on benchmark cases while remaining brittle in real emergency departments where presentations are messy and time-pressured.
[C1.5] A documentation assistant can perform well on scripted encounters and fail when a patient speaks in fragments or switches languages mid-sentence. The published number looks excellent. The tool works poorly. And the very publicness PRO celebrates becomes a stamp of approval that discourages scrutiny.
[C1.6] Third, and most dangerously, passing a benchmark creates institutional complacency. Hospitals already face alert fatigue and checkbox compliance. Add a government-backed accuracy score and the response becomes: "It met the standard—use it." Clinicians stop questioning outputs.
[C1.7] Administrators stop funding parallel oversight. When failures emerge—and they will, because benchmarks cannot anticipate every real-world scenario—the liability fog thickens because the system "passed."
[C1.8] The alternative is not anarchy. It is continuous post-deployment surveillance, mandatory incident reporting, and real-time bias audits calibrated to actual patient populations. That is how we catch failures in drugs and devices—not by trusting a pre-market test score, but by monitoring what happens when the tool meets reality.
[C1.9] Static benchmarks are a comforting illusion. Healthcare deserves better.

## Turn 3: PRO Rebuttal 1

- model: gpt-5.6-high
- raw_words: 305
- clipped_words: 305
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P2.1] CON’s case attacks a “static checkpoint” the proposition does not require. Publicly reported benchmarks are a necessary condition, not a permanent warranty or a substitute for monitoring. Benchmarks can be updated, tied to specific tasks, assessed across subgroups, and measured on the full human-AI workflow. Continuous surveillance, incident reporting, and revalidation all remain available.
[P2.2] CON offers a false choice between checking before deployment and checking afterward; safe health systems do both.
[P2.3] The “validation paradox” is equally overstated. Models can be evaluated retrospectively, in shadow mode, through supervised research pilots, and against local workflows without granting routine permission and reimbursement. Clinicians can remain the sole decision-makers while evidence is collected. What PRO rejects is scaling an unproven system and billing for it merely because real-world data would be useful.
[P2.4] Patients should not become involuntary test subjects simply because the vendor wants a larger dataset.
[P2.5] Goodhart’s Law does not justify eliminating standards. It justifies well-designed, multidimensional, revisable standards rather than one headline score. Documentation can be tested for hallucinations, omissions, and medication capture; triage can be tested for missed emergencies and subgroup error rates. Public reporting makes cherry-picking easier to expose.
[P2.6] Secrecy does not prevent gaming—it merely prevents outsiders from detecting it.
[P2.7] Nor is complacency uniquely caused by benchmarks. Clinicians can overtrust a polished interface, vendor marketing, or an administrator’s procurement decision even when no evidence exists. A public benchmark at least creates an auditable floor. Passing should never mean immunity from oversight, but failing—or refusing to disclose—should mean no routine access to patients and no reimbursement.
[P2.8] CON’s surveillance-only model discovers systematic harm after deployment. Incident reports are especially weak for errors whose victims simply wait longer or disappear into aggregate outcomes. The decisive question is who bears uncertainty. PRO places it on vendors seeking adoption and payment; CON places it on patients first and investigates later.

## Turn 4: CON Rebuttal 1

- model: mimo-v2.5-pro
- raw_words: 332
- clipped_words: 332
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C2.1] PRO's rebuttal inadvertently strengthens my position. Consider what PRO now concedes: benchmarks are "a necessary condition, not a permanent warranty," continuous surveillance remains essential, and tools can be evaluated through shadow mode and supervised pilots before formal gatekeeping. That is my case. If continuous monitoring is doing the real safety work—and PRO agrees it is—then the proposition's benchmark gate adds institutional friction and false assurance without being the primary protection.
[C2.2] The shadow-mode concession is particularly revealing. PRO says models can be evaluated retrospectively and in shadow mode "without granting routine permission and reimbursement." But shadow mode is deployment in real clinical contexts. PRO is admitting that real-world validation must precede meaningful benchmarks—exactly the validation paradox I identified.
[C2.3] The proposition doesn't facilitate this learning; it makes routine use and reimbursement contingent on clearing gates that themselves require the data that routine use produces.
[C2.4] On Goodhart's Law, PRO responds that we need "well-designed, multidimensional, revisable standards." This is aspirational, not practical. Once a benchmark determines market access, it calcifies. Revising a regulatory gate requires notice-and-comment rulemaking, political consensus, and industry negotiation.
[C2.5] Multidimensional benchmarks multiply the bureaucratic surface area without solving the fundamental problem: published scores become the metric that gets optimized rather than the clinical outcome that matters.
[C2.6] PRO's framing of "who bears uncertainty" is the wrong question. Under PRO's regime, patients bear uncertainty too—they simply face it after a government-stamped score has created institutional complacency and vendor lock-in. The relevant question is which system catches real-world failures faster. Continuous surveillance with mandatory incident reporting adapts as patterns emerge.
[C2.7] A pre-market checkpoint catches what was in the test set and misses what wasn't—which is precisely the failure mode that harms patients in novel populations, atypical presentations, and evolving clinical contexts.
[C2.8] PRO has effectively conceded that ongoing monitoring is non-negotiable. The remaining question is whether a pre-deployment benchmark gate helps or hurts. It delays beneficial tools, generates a false sense of security, and substitutes a one-time score for the adaptive oversight that actually protects patients.

## Turn 5: PRO Pressure Questions

- model: gpt-5.6-high
- raw_words: 56
- clipped_words: 56
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P3.1] Q1: If surveillance catches harm only after exposure, why should a model that fails basic accuracy or subgroup-bias benchmarks receive routine permission and reimbursement?
[P3.2] Q2: You equate shadow testing, where AI does not control care, with routine deployment. What evidence requires exposing patients before benchmarks rather than collecting real-world data through shadow mode and supervised pilots?

## Turn 6: CON Pressure Questions

- model: mimo-v2.5-pro
- raw_words: 78
- clipped_words: 78
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C3.1] Q1: You concede continuous surveillance is essential and shadow mode enables real-world evaluation before formal access. If monitoring catches failures post-deployment regardless, what does the benchmark gate uniquely accomplish beyond delaying beneficial tools and stamping them with a false assurance?
[C3.2] Q2: Your benchmarks must themselves be valid before they can protect patients. Who validates the validators, against what baseline, and what stops a well-resourced vendor from gaming a published benchmark before your continuous monitoring ever detects the mismatch?

## Turn 7: PRO Rebuttal 2

- model: gpt-5.6-high
- raw_words: 337
- clipped_words: 337
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: The benchmark gate uniquely prevents foreseeable harm before routine exposure and public payment. Surveillance catches drift, rare failures, and context-specific problems after admission; benchmarks screen out models already unable to meet minimum accuracy or subgroup-fairness standards. Those functions are complementary, not redundant. Any delay falls principally on vendors while they establish basic fitness, whereas surveillance-only shifts the cost of learning onto patients.
[P4.2] Public reporting need not imply a warranty: it can state the tested task, population, limitations, model version, and revalidation requirements. The cure for clinicians misreading evidence is clear governance, not withholding evidence.
[P4.3] A2: Validators should use clinically defined baselines: performance against clinician-reviewed cases, existing workflows, and acceptable rates of harmful errors, with subgroup analysis relevant to the intended population. Validation can combine independent testing, held-out cases, local shadow evaluation, and published methods and results. Public reporting does not require revealing every test item, so concealed holdouts can limit direct optimization. No process makes gaming impossible, but multidimensional testing, external replication, version control, and public scrutiny make it harder and more detectable.
[P4.4] An opaque vendor can game an internal test too; secrecy merely prevents anyone from finding out.
[P4.5] CON’s central inference remains backwards: because a gate is not sufficient, it supposedly is not necessary. Smoke alarms do not make fire codes pointless. Post-deployment monitoring cannot justify routine use of a system that already fails known safety tests.
[P4.6] Most importantly, CON never supplies a principled admission rule. Under surveillance-only, even a triage model with unacceptable missed emergencies or stark subgroup disparities may enter routine care and receive reimbursement, provided harm is monitored afterward. That is not adaptive oversight; it is delayed exclusion.
[P4.7] Shadow mode resolves the alleged paradox because it permits learning from clinical reality without allowing AI outputs to determine care or earn routine reimbursement. PRO therefore preserves both innovation and evidence generation. CON conflates access to evaluation with entitlement to patients and payment. The safer allocation is clear: demonstrate a public minimum first, then monitor continuously—not deploy first and make patients reveal the failure.

## Turn 8: CON Rebuttal 2

- model: mimo-v2.5-pro
- raw_words: 403
- clipped_words: 340
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6], [C4.7], [C4.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C4.1] A1: The question assumes benchmarks reliably identify models that would harm patients. A tool that genuinely cannot triage accurately will also fail continuous monitoring. The benchmark gate's distinctive contribution is catching only failures visible in a pre-deployment test set, while stamping everything that passes with a score that breeds complacency. I am not arguing failed tools should be deployed.
[C4.2] I am arguing the gate catches the easy failures—while missing novel populations, atypical presentations, and evolving contexts where real harm occurs.
[C4.3] A2: Shadow mode is precisely the mechanism I endorsed—collecting real-world data without AI outputs controlling care. PRO's move is to convert shadow data into published benchmark scores that determine reimbursement, which recreates the gaming problem. I support shadow testing as input to continuous surveillance. I oppose building a static regulatory gate on top of it.
[C4.4] The question confuses evidence collection with the checkpoint erected upon it.
[C4.5] These answers expose what has become the decisive weakness in PRO's case. Across this debate, PRO has conceded that benchmarks are not a warranty, that continuous surveillance is essential, and that shadow mode enables learning before formal access. What remains of the proposition is a gate that screens out obvious failures—which surveillance would catch anyway—while generating institutional false assurance about everything that passes.
[C4.6] In practice, the benchmark becomes the compliance event. Administrators check the box. Vendors point to the published score. Clinicians face institutional pressure to trust what was approved.
[C4.7] The gate doesn't add safety; it redirects institutional attention away from ongoing monitoring that actually catches the failures that matter. PRO calls benchmarks and surveillance "complementary," but organizations reliably substitute the easier, legible checkbox for the harder, continuous work. That is not a theoretical risk—it is how compliance culture operates in every complex institution.
[C4.8] PRO's final challenge is that I offer no principled admission rule. Continuous surveillance with mandatory incident reporting, real-time bias audits, and task-specific monitoring IS the admission rule. It just isn't a single checkpoint. The demand for a bright-line pre-deployment gate reflects regulatory instinct designed for static drugs and devices, [clipped]

## Turn 9: PRO Closing

- model: gpt-5.6-high
- raw_words: 198
- clipped_words: 198
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P5.1] The decisive question: before AI shapes routine care and receives reimbursement, must anyone publicly show it meets a minimum standard? CON ultimately says no. Continuous surveillance cannot serve as an “admission rule” because it operates after admission. It may remove a dangerous model; it cannot explain why that model deserved access and payment initially.
[P5.2] CON insists it would not deploy failed tools. But “failed” requires a standard of accuracy and subgroup fairness. Unless that standard is required and publicly reported before routine use, the promise is unenforceable: vendors can offer selective evidence, hospitals cannot compare claims, and patients cannot see who bears elevated error.
[P5.3] False confidence does not reverse this logic. Any safety approval can be misunderstood. The answer is explicit limitations and continuing monitoring, not abandoning the safety floor. A benchmark is no warranty; it is evidence that known, measurable failures were not ignored before scale.
[P5.4] Both sides permit shadow testing and post-deployment surveillance. Only PRO prevents systems from entering routine care without first showing they clear basic accuracy and bias standards. CON would let patients expose the problem later. That is the decisive allocation of risk: vendors establish fitness first; patients do not finance its discovery.

## Turn 10: CON Closing

- model: mimo-v2.5-pro
- raw_words: 236
- clipped_words: 220
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C5.1] PRO frames this as a choice between pre-deployment proof and patient exposure. The real choice is between a legible checkpoint that displaces institutional vigilance and a system of continuous accountability that catches harm where benchmarks cannot. The decisive weakness in PRO’s case is not that standards are undesirable, but that a published benchmark becomes the compliance event. Once a model passes, administrators check the box, vendors cite the score, and clinicians face pressure to trust the approved tool.
[C5.2] This is how compliance culture works in every complex institution—organizations substitute the easier, visible ritual for the harder, continuous work of monitoring.
[C5.3] PRO insists benchmarks and surveillance are complementary. But if continuous monitoring is non-negotiable—as PRO concedes—then the gate’s distinctive function is only to screen out models that would also fail ongoing scrutiny. Its real-world effect is to breed the false assurance that, because a model met a historical test, it is now safe to reduce scrutiny. That is the opposite of adaptive oversight.
[C5.4] It creates the very complacency that lets novel failures go undetected until they cause systematic harm.
[C5.5] CON does not argue for deploying tools without evidence. It argues for evidence systems that adapt with reality, not ones that fossilize trust in a single published number. The safer path is to reject the illusion of a pre-deployment safety floor [clipped]
